Trials / Active Not Recruiting
Active Not RecruitingNCT03474770
BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- Supernus Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine safety signals and demonstrate seizure reduction in adults with FIAS treated with BIS-001ER as an add-on therapy in an in-patient and out-patient study design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIS-001ER | BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A. |
Timeline
- Start date
- 2018-04-10
- Primary completion
- 2026-12-30
- Completion
- 2026-12-30
- First posted
- 2018-03-23
- Last updated
- 2022-08-30
Locations
2 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT03474770. Inclusion in this directory is not an endorsement.